Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Comment by Sandalson Jul 10, 2000 9:23am

347 Views

Post# 2175822

RE: Market Depth

Hope this looks okay... REAL-TIME MARKET BY PRICE Bid Orders Bid Vol Bid Price Ask Price Ask Vol Ask Orders 7 22,500 0.53 0.53 31,000 3 5 10,500 0.50 0.54 15,000 1 5 7,000 0.48 0.55 24,000 4 2 11,000 0.47 0.56 36,000 4 2 19,000 0.46 0.57 17,500 5

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!